1. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
   Rafaela Nasser Veiga et al, 2024, Journal of Molecular Medicine CrossRef
2. Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region
   Jie Liu et al, 2022, Analytical Cellular Pathology CrossRef
3. Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets
   João Figueira Scarini et al, 2024, Frontiers in Oncology CrossRef
4. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer
   Charles N. Landen et al, 2006, JNCI: Journal of the National Cancer Institute CrossRef
5. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
   Ahmed F. Salem et al, 2020, Pharmaceuticals CrossRef
6. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
   Jun Hasegawa et al, 2016, Cancer Biology & Therapy CrossRef
7. The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
   Jill Wykosky et al, 2008, Molecular Cancer Research CrossRef
8. Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct
   Scott A. Hammond et al, 2007, Cancer Research CrossRef
9. Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder
   Shaji Abraham et al, 2006, Clinical Cancer Research CrossRef
10. Eph-modulated Cell Morphology, Adhesion and Motility in Carcinogenesis
    Sabine Wimmer-Kleikamp et al, 2005, IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) CrossRef
11. Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists
    Amy K. Wesa et al, 2008, The Journal of Immunology CrossRef
12. Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
    Areti-Maria Vasilogianni et al, 2023, Frontiers in Oncology CrossRef
13. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
    Ahmed F. Salem et al, 2018, Journal of Medicinal Chemistry CrossRef
14. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
    Parima Udompholkul et al, 2021, Molecules CrossRef